-

Agilent Wins Multiple Innovation Awards

Leading science industry publications recognize Agilent’s advances in mass spectrometry

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that both The Analytical Scientist and The Medicine Maker have honored the Agilent InfinityLab LC/MSD iQ system with 2019 Innovation Awards.

The award-winning mass spectrometer, introduced in June 2019, incorporates intelligent ‘designed-in’ innovations such as embedded sensors that monitor instrument health and provide early maintenance feedback.

Described by The Analytical Scientist as ‘a small, high-performance system that enables MS analysis without the requirement for extensive training,’ the Agilent InfinityLab LC/MSD iQ system is specifically designed for chemists and chromatographers, to be an easy-to-use mass selective detector that provides added specificity and selectivity.

“The pharma industry seems to be on the cusp of significant change,” said Stephanie Sutton, editor of The Medicine Maker. “Especially with the emergence of advanced medicines, such as cell and gene therapies, and new digital technologies with the potential to transform how the industry manufactures medicines – large and small. We’re proud to shine a light on the important contribution made by vendors to the manufacture of medicines and, ultimately, the treatment of patients.”

“Winning these two awards is especially gratifying, as it confirms the value of our continued emphasis on innovation,” said Monty Benefiel, Agilent vice president, and general manager of the company’s Mass Spectrometry Division. “It is our hope that the InfinityLab LC/MSD iQ system will help our customers do what they do best: improve the world around us.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Catherine Kaye
Agilent Technologies
+447775 410632
catherine.kaye@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Catherine Kaye
Agilent Technologies
+447775 410632
catherine.kaye@agilent.com

More News From Agilent Technologies Inc.

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb’...

Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides...

Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to...
Back to Newsroom